📰 After First Line News
After First Line News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from After First Line. Real-time updates on events, politics, business and more.
June 7, 2022
NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient-Reported Outcomes Versus ChemotherapyPositive Interim Results in... | June 7, 2022
May 23, 2022
23.05.2022 - Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring ... Seite 1